Frank Wagner - Concepedia

Author

Frank Wagner

Also Known As

F D Wagner, F Wagner, F. Wagner, F.D Wagner, F.D. Wagner, Frank D Wagner, Frank D. Wagner, Frank Dietrich Wagner, Frank Wagner, Franz-Josef Wagner

130

Publications

3.2K

Citations

H-Index

Concepts

All Affiliations

Charité - Universitätsmedizin Berlin Novartis (Switzerland)Deutsches Herzzentrum der Charité Merck & Co., Inc., Rahway, NJ, USA (United States)Unilever (Netherlands)

About

Frank Wagner is an author at Charité - Universitätsmedizin Berlin specializing in medicine, immunology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	1.3K
2	Engineering	1	1	59
3	Health Sciences	1	1	24
4	Public Health	1	1	32
5	Allergy	1	1	163

Frank Wagner

Publications

3.1K

Citations

H-Index

Page 1

	Year	Citations
SCH 503034, a Novel Hepatitis C Virus Protease Inhibitor, Plus Pegylated Interferon α-2b for Genotype 1 Nonresponders Christoph Sarrazin, Frank Wagner, Nicole Forestier, Gastroenterology HepatologyViral HepatitisImmunologyAntiviral Drug DevelopmentHepatitis	2007	311
Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study Alain C. Tissot, Patrik Maurer, Juerg Nussberger, The Lancet HypertensionAngiotensin IiCardiovascular DiseaseAmbulatory Blood PressureAntihypertensive Therapy	2008	284
Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial James G. Krueger, Laura K. Ferris, Alan Menter, Journal of Allergy and Clinical Immunology ImmunologyClinical TrialsBiomarker ResultsClinical DermatologyPlacebo-controlled Trial	2015	246
A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity Patrice M. Ambühl, Alain C. Tissot, Alma Fulurija, Journal of Hypertension	2006	218
Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity Thomas Dörner, Maximilian Posch, Yue Li, Annals of the Rheumatic Diseases	2019	189
The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma Kai-Michael Beeh, Frank Kanniess, Frank Wagner, Journal of Allergy and Clinical Immunology AsthmaAllergyAllergy MedicineMedicineImmunology	2013	163
A novel dual glucagon‐like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo‐controlled first‐in‐human and first‐in‐patient trials J. Tillner, Maximilian Posch, Frank Wagner, Diabetes Obesity and Metabolism	2018	160
The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study Roland E. Schmieder, Frank Wagner, Michael Mayr, European Heart Journal	2017	155
A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE) Marcelo Silva, Jorge Luis Poo, Frank Wagner, Journal of Hepatology HepatologyHepatitis CViral HepatitisMedicineRandomised Trial	2006	106
Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis Cris S. Constantinescu, Aliya Asher, Waldemar Fryze, Neurology Neuroimmunology & Neuroinflammation	2015	103

Page 1